The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands

N. Van der Linden*, S. Van Olst, S. Nekeman, C. A. Uyl-de Groot

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science